Mizuho Increases American Tower (AMT) Price Target to $217, Affirms 'Outperform'
A technician working on a mobile device, indicating the company's wireless internet access capabilities.
Mizuho noted the American Tower's 'stable revenue base,' supported by long-term lease agreements with major wireless carriers, which provide predictable cash flows. The analysts also highlighted the company's 'portfolio expansion,' particularly its growing presence in data centers and international markets, as a key driver of future growth. They further pointed to the company's first-quarter 2025 performance, with organic tenant billings growth of 4.3% domestically and 6.1% internationally, as evidence of operational strength.
At the same time, Mizuho increased its Adjusted Funds From Operations (AFFO) estimates to $10.53 for 2025 and $11.43 for 2026, up from prior estimates of $10.47 and $11.27, respectively. The upward revision is attributed to a lower-than-expected foreign exchange impact and stronger services revenue. The firm projects approximately 5% organic growth in tenant billings for American Tower's entire portfolio. Additionally, Mizuho's analysis suggests that growth in U.S. and Canadian operations is anticipated to be around 4.3%, resulting in approximately $182 million in colocation and amendment revenue.
American Tower Corporation (NYSE:AMT) is a global infrastructure REIT that owns and operates over 148,000 wireless communication sites across 22 countries on five continents. This includes a growing portfolio of U.S. data center facilities. Headquartered in Boston, the company leases multitenant towers and rooftop sites to wireless carriers, broadcasters, and government agencies, generating stable, long-term recurring revenue.
While we acknowledge the potential of AMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Goldman Sachs Healthcare Stocks: Top 10 Stock Picks and 11 Best Green Energy Penny Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Error in retrieving data
Sign in to access your portfolio
Error in retrieving data
Error in retrieving data
Error in retrieving data
Error in retrieving data
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Trailhead Biosystems® Expands Human Cell-Based Product Line with iPSC-Derived A9 Dopaminergic Neurons
BEACHWOOD, Ohio, July 23, 2025 /CNW/ -- Trailhead Biosystems, Inc. ( a biotechnology company pioneering the creation of induced pluripotent stem cell (iPSC)-derived human cells at scale for drug discovery and cell therapy, introduces TrailBio® A9 Dopaminergic Neurons, a powerful new tool available off-the-shelf for studying Parkinson's disease and other neurodegenerative conditions. A9 dopaminergic neurons play a critical role in movement regulation and are disproportionately affected in Parkinson's disease. Historically, researchers have lacked access to viable human models, relying instead on animal studies with limited relevance. With TrailBio® A9 Dopaminergic Neurons, scientists now have a human-specific platform to investigate disease mechanisms, develop therapies and accelerate drug discovery. "TrailBio® A9 Dopaminergic Neurons open new possibilities for Parkinson's research," said Dr. Jan Jensen, Chief Scientific Officer, Chief Technology Officer and founder of Trailhead Biosystems. "These cells enable researchers to study the vulnerabilities of A9 neurons, helping drive progress toward more effective treatments." "For decades, the lack of human A9 neurons has limited our ability to truly understand Parkinson's disease," added Dr. Nooshin Amini, Scientific Director at Trailhead Biosystems. "Now, with TrailBio® A9 Dopaminergic Neurons, researchers can directly study the exact cells that are most affected, offering hope for groundbreaking insights and future therapies." About Trailhead Biosystems Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen. Trailhead creates optimized human cells at scale with its proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, integrating advanced mathematical modeling with high-throughput robotic manufacturing. This innovative system allows Trailhead to develop specialized, high-quality iPSC-derived human cells for drug discovery and cell-based therapies. TrailBio® A9 Dopaminergic Neurons represent one of many specialized human cell types emerging from this platform, with additional cell models expected in the near future. Learn more about Trailhead Biosystems, TrailBio® A9 Dopaminergic Neurons and HD-DoE® at For more information, please contact: Tim Mauk, Corporate CommunicationsTrailhead BiosystemsEmail: info@ View original content to download multimedia: SOURCE Trailhead Biosystems Inc View original content to download multimedia:
Yahoo
4 minutes ago
- Yahoo
S&P 500 Is Getting More Bitcoin Exposure as Block Joins the Club
Block, Jack Dorsey's Bitcoin-focused payments company, is set to join the S&P 500 on Wednesday, a milestone moment for both the company and and foray further into crypto for the benchmark index. Block (XYZ), which was rebranded from Square in 2021, is the second blockchain company to join the club after cryptocurrency exchange Coinbase Global (COIN) was added to the index in mid-May. That means index fund investors will get a modest bump in exposure to the world's largest cryptocurrency bitcoin (BTCUSD). The company takes the spot vacated by Hess Corp., which was acquired by Chevron (CVX) in a deal that closed July 18. It's the third addition of the month, following The Trade Desk (TTD) and Datadog (DDOG). Since the announcement of Block's inclusion late Friday, the shares have risen 9%. Block's stock has benefited from an index effect, which refers to directional pressure on stocks when a company is added to, or removed from, the S&P 500 and other indexes. The most recent research report on the matter from S&P Dow Jones Indices, which studied the price impact of index additions and deletions from 1995 to June 2021, showed that it isn't always much of a force. The median excess returns—defined here as the difference between a stock's total return and that of the broader index—of stocks added to the index, measured from the announcement date to the effective date, was about 8% from 1995 to 1999. From 2000 to 2010, that number shrank to 3.6%, and was essentially nonexistent from 2011 to 2021. And even if an index effect shows up ahead of the official inclusion or deletion date, according to a McKinsey study, the premium or discount has a tendency to dissipate within a few months. What's new can get old pretty fast. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
Texas Instruments shares sink as tariff risks cloud chip demand outlook
(Reuters) -Texas Instruments shares slumped nearly 12% in premarket trading on Wednesday, after its quarterly profit forecast indicated a hit to demand for its analog chips that stoked investor fears of tariff-related disruptions. The dour third-quarter profit forecast contrasts with its earlier hopes for a strong rebound in chip demand, increasing concerns about tariff impacts and tempering investor confidence. In response to analysts' questions on a post-earnings call about whether tariffs were prompting customers to pull in orders and bumping up revenue, TI CEO Haviv Ilan said he "can't rule out the possibility". "(TI's) tone has shifted markedly vs last quarter's call as well as vs management's intra-quarter commentary, with seemingly more caution around the geopolitical and tariff environment," said Bernstein analyst, Stacy Rasgon, adding that the shift "felt somewhat sudden". Chipmakers like TI are not directly affected by Trump's higher tariffs yet, but rising costs for chip-making tools and reduced spending by some customers are starting to have an impact. This was evident in the broader semiconductor industry, with both ASML, the biggest supplier of chip-making equipment globally, and TSMC, the world's biggest chipmaking factory, last week, warned about tariff-related uncertainty. "The impact of tariffs/trade is beginning to emerge and we anticipate a continuation of a slightly weaker than seasonal demand environment as the year progresses due to the impact of tariffs," said analysts at J.P. Morgan. Some analysts also expressed concerns about pressure to TI's margins due to the company's rising investments to expand its U.S. manufacturing footprint. Following the results, at least six brokerages cut price targets on the stock, while three raised, as per data compiled by LSEG. The firm is up about 15%, while peer Analog Devices has gained around 11%, so far this year. TI has a 12-month forward price-to-earnings ratio of 34.66, compared to Analog Devices' 27.64.
